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Background: Concurrent radiochemotherapy is a recommended treatment option for patients with locally
advanced squamous cell head and neck carcinomas with recent data showing the most significant absolute overall
and event-free survival benefit achieved in patients with oropharyngeal tumours. The aim of this study was to
analyse the results of three-dimensional conformal radiotherapy given with concomitant weekly cisplatin in patients
with advanced oropharyngeal carcinoma and to identify prognostic factors influencing outcomes of this patients
category.
Methods: Sixty-five patients with stage III or IV squamous cell carcinoma of the oropharynx who underwent
concurrent radiochemotherapy between January 2005 and December 2010 were retrospectively analyzed. All
patients received radiotherapy to 70 Gy/35 fractions/2 Gy per fraction/5 fractions per week. Concurrent
chemotherapy consisted of weekly cisplatin (30 mg/m2) started at the first day of radiotherapy.
Results: Median age was 57 years (range, 36 to 69 years) and 59 (90.8%) patients were male. Complete composite
response was achieved in 47 patients (72.3%). Local and/or regional recurrence was the most frequent treatment
failure present in 19 out of 25 patients (76.0%). At a median follow-up of 14 months (range, 5 to 72 months), 2-year
local relapse-free, regional relapse-free, locoregional relapse-free, disease-free, and overall survival rates were 48.8%,
57.8%, 41.7%, 33.2% and 49.7%, respectively.
On multivariate analysis the only significant factor for inferior regional relapse-free survival was the advanced N
stage (p = 0.048). Higher overall stage was independent prognostic factor for poorer local relapse-free survival,
locoregional relapse-free survival and disease-free survival (p = 0.022, p = 0.003 and p= 0.003, respectively). Pre-
treatment haemoglobin concentration was an independent prognostic factor for local relapse-free survival, regional
relapse-free survival, locoregional relapse-free survival, disease-free survival, and overall survival (p = 0.002, p = 0.021,
p = 0.001, p = 0.002 and p= 0.002, respectively).
Conclusions: Poor treatments results of this study suggested that introduction of intensity-modulated radiotherapy,
use of induction chemotherapy followed by concurrent radiochemotherapy, accelerated radiotherapy regimens,
and molecular targeted therapies could positively influence treatment outcomes. The incorporation of reversal of
anaemia should be also expected to provide further improvement in locoregional control and survival in patients
with advanced squamous cell carcinoma of the oropharynx.
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Squamous cell carcinoma of the oropharynx is the
eleventh most common cancer worldwide [1] with an
annual incidence of 0.8 per 100000 [2]. Besides the
strong association of oropharyngeal carcinoma with
tobacco and alcohol abuse observed in epidemiological
and clinical studies [3], the specific association of this
cancer with human papillomavirus (HPV) infection has
been now well-known [4,5]. The tonsil is the most fre-
quently represented subsite of the primary oropharyn-
geal carcinoma followed by the base of tongue [6,7].
These two subsites account for between 80–90% of cases
[2]. Oropharyngeal carcinomas are usually diagnosed as
locoregionally advanced disease [8,9]. Thus, most of the
primary tumours presents at an advanced stage (T2 or
greater) [10], and the incidence of nodal metastases
ranges between 60-70% [11,12] which is probably related
to the rich lymphatic supply of the dominant subsites of
the oropharyngeal cancers.
Treatment decision making process for oropharyngeal
carcinomas arising in this functionally important ana-
tomic region must take into consideration not only the
most optimal treatment strategy for local/regional
tumour control achievement but also the associated
morbidity to this critical site in the upper aerodigestive
tract. The treatment for advanced but resectable oropha-
ryngeal carcinoma has traditionally been radical surgery
and postoperative radiotherapy often resulting in sub-
optimal rates of locoregional control (LRC) and signifi-
cant long-term functional deficits, or radiotherapy alone
for advanced unresectable lesions inducing long-term
toxicities accompanied with initial affection of speech
and swallowing as a consequence of the primary tumour
growth. However, in the last two decades, several rando-
mized studies and meta-analyses indicated that concur-
rent radiochemotherapy (CRCT) has been shown to
provide an improvement in LRC and survival as well as
a significant increase in the rate of organ preservation
when compared with radiation alone in patients with
advanced head and neck cancer including those pre-
sented with advanced oropharyngeal carcinoma [13-22].
Apart from the trials including multiple sites in the head
and neck cancers, the French Head and Neck Oncology
and Radiotherapy Group (GORTEC 94-01) phase III
randomized trial analyzing separately squamous cell car-
cinomas arising from the oropharynx established CRCT
as the standard treatment for locoregionally advanced
oropharyngeal cancer over conventional radiotherapy
alone [23]. CRCT has been shown superior as compared
with radiotherapy alone with regard to LRC, disease-free
survival (DFS) and overall survival (OS) [23]. The final
results of this trial reported in 2004 also confirmed that
CRCT improved OS and LRC rates in patients with
advanced oropharyngeal carcinoma [24]. Consequently,CRCT has been adopted as a preferred treatment ap-
proach that enables an achievement of increased rate of
disease control with anatomic and physiologic function
preservation [25]. Recently, in order to reveal the magni-
tude of the benefit of addition of chemotherapy to radio-
therapy in terms of OS in head and neck squamous cell
carcinoma according to tumour site, a comprehensive
analysis was performed using individual data of 16,192
patients included in the meta-analysis of chemotherapy
in head and neck cancer (MACH-NC) [26]. The inter-
action test showed the most significant effect of chemo-
therapy timing (p< 0.0001) in the oropharynx cancers
group which was the largest group analysed consisting
of 5878 patients, suggesting a significantly better effect
of platinum-based concurrent chemotherapy [26]. Al-
though the superiority of platinum-based chemotherapy
has been confirmed in the meta-analysis of the MACH-
NC Collaborative Group [19] and in the meta-analysis of
Browman et al. [21], regarding the question about the
number of chemotherapeutic agents and schedules of
drug delivery, the optimum regimen seems to remain
unclear. The most common method used worldwide was
delivery of cisplatin every 3 weeks [17,27]. However,
based on the assumption that more frequent drug ad-
ministration could provide greater radiosensitizing bene-
fit and taking into account the less induced morbidity
with smaller individual doses of drug without comprom-
ising treatment efficacy [28], weekly administration of
single-platinum agent has been also studied [29,30] al-
though this schedules utilizing smaller doses more fre-
quently has been not compared directly with the cyclical
approach to delivery of concurrent cisplatin [31].
Regarding the radiotherapy techniques employed, it
should be mentioned that the introduction of defini-
tive three-dimensional conformal radiotherapy
(3DCRT) with or without chemotherapy as the stand-
ard of practice in the treatment of oropharyngeal can-
cer in clinics around the world with tight target
definitions of the primary tumour, metastatic nodes
in the neck and neck nodal levels, enabled improve-
ment of tumour coverage while sparing the surround-
ing critical tissues [32]. Recently, intensity-modulated
radiotherapy (IMRT) achieving higher total doses in
tumours by delivering larger doses per fraction to the
tumour only, has also been shown as an effective
treatment technique for locally advanced oropharyn-
geal carcinoma [33] offering tumour control rates
kept at least at the level of 3DCRT while limiting
dose to nearby normal tissues, e.g., the parotid glands
[34,35]. Additionally, the Memorial Sloan-Kettering
Cancer Centre experience and the University of Califor-
nia-San Francisco experience has revealed encouraging
local control with acceptable treatment toxicity achieved
using IMRT chemoradiation for treatment of stage III and
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results of radiochemotherapy utilizing IMRT for advanced
stage oropharyngeal carcinoma in the prospective study
conducted by Feng et al. [38] demonstrated the possibility
of this treatment approach to reduce post-therapy func-
tional impairment obtaining at the same time high rates of
locoregional tumour control.
The objective of this retrospective study was to
summarize the results of treatment following 3DCRT
and concomitant chemotherapy in patients with
advanced oropharyngeal squamous cell carcinoma as
well as to examine and identify the influence of various
patient and tumour-related prognostic factors on local
control, regional control, and survival in this patients
population. We also considered that this retrospective
analysis will give us an opportunity to compare results
obtained with CRCT with those that would be achieved
with IMRT whose implementation in the treatment of
advanced oropharyngeal carcinomas at our institution
has been started recently.
Methods
This study is based on a retrospective analysis of 65 con-
secutive patients with previously untreated, stage III or
IV primary squamous cell carcinoma of the oropharynx
without distant metastases, at the age of at least 18 years
and not more than 70 years and performance status 0 to
1, that underwent CRCT between January 2005 and De-
cember 2010 at the University Clinic of Radiotherapy
and Oncology in Skopje.
Detailed patients evaluation prior to treatment
included complete medical history with attention paid to
disease-related signs and symptoms, and tobacco or al-
cohol abuse, clinical examination and fiberoptic endos-
copy with biopsy, fine-needle aspiration biopsy in cases
with detectable neck adenopathy, computed tomography
(CT) scanning and/or magnetic resonance imaging
(MRI) of head and neck region, chest x-ray, liver ultra-
sound, complete blood count, basic blood chemistry,
and liver and renal function tests. Patients were staged
according to the 2002 classification of the American
Joint Committee on Cancer Staging (AJCC) [39].
Treatment
3DCRT was performed on a linear accelerator using
photons with beam qualities of 6 MV and 15 MV and
electrons with energies 9-16 MeV. In patients with
clinically negative neck the gross tumour volume (GTV)
was represented by the gross tumour volume of the pri-
mary tumour (GTVt70) only and defined as any visible
tumour revealed on imaging studies and/or physical
examination. In patients with clinically positive neck the
GTV was an union of GTVt70 and GTVn70. The
GTVn70 was defined as the gross nodal disease revealedon imaging studies and/or physical examination. Neck
lymph nodes were considered metastatic when their
smallest axis diameter was greater than 1.0 cm. The
clinical target volume (CTVt50) encompassed the
GTVt70 plus a margin of 1.0-2.0 cm for the potential
microscopic extension of the disease according to
anatomical barriers. The CTVn50 encompassed the
metastatic lymph node(s) if present plus at least 0.5-
1.0 cm margins. This volume also included node
levels in the neck according to the nodal status (bilat-
eral level II, III and IV in patients with clinically
negative neck, and bilateral level Ib, II, III, IV, V and
retropharyngeal lymph nodes in patients with nodal
disease). Retrostyloid space was also included in cases
with positive lymph node(s) in level II. Delineation of
the neck lymph node levels was realized according to
Danish Head and Neck Cancer Group (DAHANCA),
European Organization for Research and Treatment
of Cancer (EORTC), Groupe d'Oncologie Radiothéra-
pie Tête et Cou (GORTEC), National Cancer Institu-
teof Canada (NCIC), Radiation Therapy Oncology
Group (RTOG) consensus guidelines [40] and propo-
sals for the delineation of the nodal clinical target
volume in the node positive and the postoperative
neck [41]. CTV50 was created by integration of
CTVt50 and CTVn50. The planning target volumes
were PTV50 and PTV70. The PTV50 provided a mar-
gin of 0.5 cm around CTV50. The PTV70 encom-
passed the GTV plus a 0.5 cm margin. Conventional
fractionation was used with a daily dose of 2.0 Gy, 5 times
per week.
Chemotherapy was administered with radiation in
concomitant setting. The regimen used consisted of
weekly cisplatin (30 mg/m2) started at the first day of
radiotherapy. Cisplatin was given before irradiation and
the time gap between cisplatin administration and radio-
therapy was no longer than three hours. Hydration and
antiemetics were delivered according to standards of
care. Complete blood count and biochemical analysis of
serum urea and creatinine were done every week.
Response assessment and follow-up
Evaluation of tumour response was performed 3 months
after the completion of CRCT by physical examination,
fiberoptic endoscopy, and CT or MRI of the primary site
and the neck. Endoscopy under anaesthesia and biopsy
of any clinical, endoscopic or radiological abnormality
found was performed to reveal and confirm the suspi-
cious residual lesion. Response to treatment was docu-
mented by the World Health Organization (WHO)
response grading system [42]. Complete response of the
primary tumour was defined as complete disappearance
of all detectable disease at the primary site to visual in-
spection and imaging studies. Complete response of the
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all nodal disease on clinical examination and imaging
studies. Complete composite response was defined as
complete disappearance of locoregional disease. Partial
response was defined as tumour reduction by at least
50% of the sum of the product of perpendicular dia-
meters of all measurable lesions on endoscopy and im-
aging studies without any appearance of new lesions.
Patients were followed up every month over the first
year after treatment, every 2 months in the second year
after treatment, every 3 to 6 months in the third through
the fifth years after treatment, and every 12 months
thereafter. Each follow-up examination included history,
physical examination, and fiberoptic endoscopy, or indir-
ect mirror exam. Diagnostic imaging of the head and
neck region was performed in any patient with signs and
symptoms suggesting recurrence development with bi-
opsy performed in order to obtain histological proof of
clinically suspicious recurrent disease.
Statistical analysis
All patients were included in the survival analysis. Statis-
tical end points of this study were local relapse-free sur-
vival (LRFS), regional relapse-free survival (RRFS),
locoregional relapse-free survival (LRRFS), DFS, and OS.
LRFS for patients with complete response of the primary
tumour was measured from the day of treatment start to
the date when reappearance of primary disease was first
recorded, or to the date of the last follow-up. For
patients with persistent primary disease LRFS was mea-
sured from the first day of treatment to the date of the
first follow-up visit. RRFS for patients with clinically
negative neck and for those who achieved complete re-
sponse of the nodal disease following treatment was
measured from the day of treatment start to the date
when appearance of metastatic lymph nodes in the neck
or recurrence of the neck disease was first recorded, or
to the date of the last follow-up. For patients with per-
sistent nodal disease RRFS was measured from the first
day of treatment to the date of the first follow-up visit.
LRRFS for patients who achieved complete composite
response to CRCT was measured from the first day of
treatment to the date of reappearance of disease either
at the primary site and/or regional lymph nodes, or until
the day of the last follow-up. For patients initially staged
as N0 who manifested complete primary response to
treatment, LRRFS was calculated from the date of treat-
ment beginning until the date when appearance of meta-
static lymph node(s) in the neck and/or reappearance of
disease at the primary site were first reported, or to the
last follow-up date. DFS was calculated from the date of
commencement of treatment to the date when local, re-
gional, locoregional or distant failure was first recorded
or, in the case of local and/or regional persistent disease,to the date of first follow-up visit. OS was measured
from the start date of treatment to the date of the last
follow-up or to the date of death from any cause. LRFS,
RRFS, LRRFS, PFS and OS were calculated using the
method of Kaplan-Meier [43].
Gender, age at diagnosis (≤ 50 years vs. > 50 years ),
Eastern Cooperative Oncology Group (ECOG) perform-
ance status (0 vs. 1), cigarette smoking (non-smokers vs.
current smokers), alcohol consumption (non-drinkers
vs. current drinkers), subsite at the primary site (tonsil
vs. base of tongue vs. soft palate vs. posterior pharyngeal
wall), T stage (T2-3 vs. T4), N stage (N0-1 vs. N2-N3),
overall stage (III vs. IVA-B), histological differentiation
(well vs. moderate vs. poor), and haemoglobin concen-
tration before treatment (≤ 12.5 g/dL vs. > 12.5 g/dL)
were also assessed as potential prognostic factors investi-
gating their impact on LRFS, RRFS, LRRFS, DFS, and
OS using the log-rank test and p index. Cox's regression
model was used for multivariate analysis. Statistical sig-
nificance was defined as p-value less than 0.05. Multi-
variate analysis included those prognostic factors that
had displayed p-value< 0.05 in the univariate analysis.
Results
Patient and tumour characteristics
There were 59 (90.8%) males and 6 (9.2%) females studied.
Median age was 57 years (range, 36 to 69 years). Mean
age was 56.4 years ± 8.33 SD. Forty four patients (67.7%)
were presented with ECOG performance status 0 and 21
patients (32.3%) had ECOG performance status 1. Regard-
ing the cigarette smoking status, more than four fifths of
patients (83.1%) were current smokers while only 11
patients (16.9%) were considered non-smokers (patients
who never smoked or those who quitted smoking more
than 3 years ago). Likewise, regarding the drinking status,
almost two thirds of patients (25/65 [61.5%]) were current
alcohol drinkers while 25 patients (38.5%) were considered
non-drinkers (patients who never drunk and those who
quitted alcohol consumption more than 3 years ago). The
level of haemoglobin> 12.5 g/dL before treatment com-
mencement was measured in 45 patients (69.2%). Haemo-
globin concentration≤ 12.5 g/dL was present in 20
patients (30.8%). The subsites of the primary tumour trea-
ted were: tonsil 36 (55.4%), base of tongue 21 (32.3%), soft
palate 6 (9.2%), and posterior pharyngeal wall 2 (3.1%).
The distribution according to AJCC of overall stages was
as follows: stage III 23 (35.4%), stage IVA 36 (55.4%), and
stage IVB 6 (9.2%). The distribution of T and N stages as
well as the distribution of degrees of histological differen-
tiation is provided in Table 1.
Compliance of treatment
All patients received the prescribed total radiotherapy
dose (70 Gy). In vast majority of patients (55 patients,
Table 1 Tumour characteristics (n = 65)
Characteristics No. of patients %
Subsite of the primary tumour
Tonsil 36 55,4
Base of tongue 21 32,3
Soft palate 6 9,2


















Table 2 Response to treatment in accordance with the













Tonsil 26/36 (72.2%) 16/25 (64.0%) 25/36 (69.4%)
Base of tongue 16/21 (76.2%) 12/15 (80.0%) 16/21 (76.2%)
Soft palate 4/6 (66.7%) 2/4 (50.0%) 4/6 (66.7%)
Posterior wall 2/2 (100.0%) 1/1 (100.0%) 2/2 (100.0%)
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pletion was ≤ 7 weeks. Ten patients (15.4%) required
greater than 7 weeks to complete treatment with inter-
ruptions due to a variety of causes including comorbid-
ity. Sixty per cent of patients completed all seven cycles
of concurrent chemotherapy, and the remaining 40%
received six cycles of concurrent weekly cisplatin. The
mean total dose of cisplatin given was 192 mg/m2± 14.8
SD.
Response to treatment
Complete response at the primary site was seen in 48
patients (73.8%). Complete response of the metastatic
lymph node(s) in the neck occurred in 31 patients
(68.9%). Complete composite response was present in 47
patients (72.3%). Partial composite response was regis-
tered in 18 patients (27.7%). Isolated residual disease at
the primary site was seen in two patients and at the
nodal site in only one patient. There was no salvage neck
dissection performed for residual neck disease. Detailed
data about complete response following treatment in ac-
cordance with the subsite of the primary tumour are
listed in Table 2. There was an almost equal complete
response rate at the primary site revealed in patients
with carcinoma of the tonsil and carcinoma of the baseof tongue whereas complete response rate of the nodal
disease was slightly higher in patients with base of
tongue cancer.
Patterns of failure
The median follow-up was 14 months (range, 5 to 72
months) and 19 months (range, 10 to 72 months) for all
and for living patients respectively. Treatment failure oc-
curred in 25 of 47 patients (53.2%) with complete remis-
sion at three months post-treatment assessment. Local
recurrence was noted in 9 patients, isolated regional re-
currence was present in 3 patients, and 7 patients devel-
oped locoregional recurrence. Not one of the patients
with local, regional, or locoregional recurrence was trea-
ted with salvage surgery. Distant metastases were
detected in 8 patients with complete remission following
CRCT. In two of these patients distant metastases devel-
opment was preceded by occurrence of locoregional fail-
ure. Distant metastases were also manifested in 2
patients with persistent locoregional disease following
treatment. The overall incidence of distant metastases
was 15.4% (10/65). The lungs were the most frequent
site of distant metastases (70%). The distribution of pat-
terns of failure is illustrated in Figure 1. The median
time to occurrence of local recurrence, regional recur-
rence, locoregional recurrence and distant metastases
was 12 months (range 9-35), 20 months (range 10-22),
10 months (range 8-17) and 12 months (range 7-20 ),
respectively.
Survival
LRFS, RRFS, LRRFS, DFS, and OS rates at 2 years were:
48.8%, 57.8%, 41.7%, 33.2% and 49.7%, respectively
(Figure 2). The median duration of LRFS and RRFS sur-
vival was 12 months (range 2.5-72) and 13 months
(range 2.5-72), respectively. The median duration of
LRRFS and DFS was 12 months (range 2.5-72), and the
median duration of OS was 15 months (range 7-72).
There have been 32 deaths over the period of study:
18 were from the progression of local, regional, or locor-
egional persistent disease, 5 due to local recurrence, 2
due to regional recurrence, 4 due to recurrence at both








Regional N=10 Distant N=8 
Figure 1 Venn diagram of patterns of failure.
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metastases development. At the time of analysis 33
patients were alive. Twenty two of them were registered
without disease at the last follow-up visit.Univariate analysis for prognostic factors
Univariate analysis of the eleven variables allowed the
identification of factors significantly associated with
prognosis. The results of univariate analysis for factors
influencing LRFS, RRFS, and LRRFS are shown in
Table 3. Statistically significant differences in LRFS,
RRFS and LRRFS rates were associated with ECOG per-
formance status, alcohol consumption, N stage, overall
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Figure 2 Local relapse-free survival, regional relapse-free
survival, locoregional relapse-free survival, disease-free
survival, and overall survival rates for all patients.smoking was revealed as a factor significantly associated
with RRFS and LRRFS. There was a statistically signifi-
cant difference in LRRFS associated with T stage.
Patients with ECOG performance status 1 had signifi-
cantly poorer LRFS, RRFS and LRRFS compared with
patients with performance status ECOG 0 (p = 0.0004,
p = 0.0169 and p = 0.0004, respectively). Current drinkers
had significantly worse LRFS, RRFS and LRRFS com-
pared with non-drinkers (p = 0.0163, p = 0.0222 and
p = 0.0094, respectively). Kaplan-Meier curves of LRFS in
relation with alcohol consumption are shown in Figure 3.
Higher N stage (N2-3) had a significant negative influ-
ence on LRFS, RRFS and LRRFS in comparison with
clinically negative neck and low N stage (N0-1)
(p = 0.0006, p< 0.0001, and p< 0.0001, respectively).
Kaplan-Meier curves of RRFS related to N stage are
shown in Figure 4. Overall stage IVA-B had also signifi-
cant negative impact on LRFS, RRFS and LRRFS
compared with stage III disease (p = 0.0002, p< 0.0001,
and p< 0.0001, respectively). Kaplan-Meier curves of
LRRFS in relation with overall stage are depicted in
Figure 5. Patients with pre-treatment haemoglobin
level ≤ 12.5 g/dL had worse prognosis related to LRFS,
RRFS and LRRFS compared with the group of patients
with pre-treatment haemoglobin level> 12.5 g/dL
(p< 0.0001, p = 0.0046 and p< 0.0001, respectively). The
rates of RRFS and LRRFS were significantly lower in
current smokers compared with non-smokers
(p = 0.0365 and p = 0.0475, respectively). Primary lesions
classified as T4 had significant negative influence on
LRRFS in comparison with lesions classified as T2-3
(p = 0.0451).
The impacts of the variables on DFS and OS are sum-
marized in Table 4. The results of the univariate analysis
revealed ECOG performance status, alcohol consumption,
T stage, N stage, overall stage and pre-treatment haemoglo-
bin level as significant prognostic factors for both DFS and
OS whereas the smoking status was identified as a signifi-
cant prognostic factor for DFS only. There were statistically
significant lower rates of DFS and OS in patients with
ECOG performance status 1 (p< 0.0001 for both), in those
patients who were current drinkers (p=0.0080 and
p=0.0333, respectively), in the group of patients with T4
primary lesion (p=0.0033 and p=0.0455, respectively), in
patients with advanced nodal disease (N2-3) (p=0.0004 for
both), in those patients with overall stage IVA-B (p< 0.0001
and p=0.0006, respectively), and in patients with pre-treat-
ment haemoglobin level≤12.5 g/do (p< 0.0001 for both).
Statistically significant lower DFS was present in patients
who were classified as current smokers (p=0.323). Kaplan-
Meier curves of DFS related to the T stage are shown in
Figure 6. Kaplan-Meier curves of OS in relation with the
pre-treatment haemoglobin concentration are shown in
Figure 7.
Table 3 Univariate analysis correlating prognostic factors with disease control above clavicles
Factor LRFS RRFS LRRFS
n 2 years % p-value 2 years % p-value 2 years % p-value
Gender
Male 59 45.2 0,2713 52.3 0,0527 36.2 0,1562
Female 6 83.0 100.0 83.3
Age (years)
≤ 50 20 49.3 0,7046 42.3 0,3524 30.7 0,6735
> 50 45 48.2 63.2 44.8
Performance status (ECOG)
0 44 62.8 0,0004 68.3 0,0169 54.7 0,0004
1 21 19.2 20.8 9.8
Cigarette smoking
Non-smokers 11 77.7 0,1651 89.8 0,0365 79.9 0,0475
Current smokers 54 43.2 49.8 33.8
Alcohol consumption
Non-drinkers 25 71.8 0,0163 75.3 0,0222 64.7 0,0094
Current drinkers 40 34.8 47.2 27.2
Subsite
Tonsil 36 42.8 0,3656 58.7 0,7991 37.8 0.4509
Base of tongue 21 66.7 54.7 45.9
Soft palate 6 49.2 50.2 50.9
Posterior pharyngeal wall 2 0 0 0
T stage
T2-3 47 54.0 0,1094 58.8 0,9960 49.1 0,0451
T4 18 35.4 48.1 21.6
N stage
N0-1 34 68.8 0.0006 93.8 <0.0001 66.6 <0.0001
N2-3 31 28.3 22.2 16.4
Overall stage
III 23 81.7 0.0002 95.3 <0.0001 81.6 <0.0001
IVA-B 42 30.8 33.2 19.1
Histological differentiation
Well 22 57.2 0,1931 59.2 0,1385 44.1 0,2296
Moderate 25 54.3 76.3 54.7
Poor 18 31.8 36.3 23.4
Haemoglobin level
≤ 12.5 g/dL 20 21.3 <0.0001 44.2 0,0046 19.0 <0.0001
> 12.5 g/dL 45 60.1 65.8 51.5
n, number of patients; LRFS, local relapse-free survival; RRFS, regional relapse-free survival; LRRFS, locoregional relapse-free survival; ECOG, Eastern Cooperative
Oncology Group.
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The results of multivariate analysis performed using the
prognostic factors confirmed as significant in the univari-
ate analysis are depicted in Table 5 and Table 6. The
advanced N stage was revealed as an independent prog-
nostic factor for inferior RRFS (N2-3 vs. N0-1, p = 0.048).The advanced overall stage was found to be an independ-
ent factor negatively influencing LRFS (IVA-B vs. III,
p = 0.022), LRRFS (IVA-B vs. III, p = 0.003), and DFS
(IVA-B vs. III, p = 0.003). Haemoglobin level was also in-
dependently prognostic for lower rates of LRFS (≤ 12.5 g/
dL vs. > 12.5 g/dL, p = 0.002), RRFS (≤ 12.5 g/dL vs. >


















Figure 3 Local relapse-free survival according to alcohol
consumption (Kaplan-Meier estimates) Log-rank test; Chi
square = 5.773; p = 0.0163.


















Figure 5 Locoregional relapse-free survival according to overall
stage (Kaplan-Meier estimates) Log-rank test; Chi
square = 18.88; p< 0.0001.
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p = 0.001), DFS (≤ 12.5 g/dL vs. > 12.5 g/dL, p = 0.002),
and OS (≤ 12.5 g/dL vs. > 12.5 g/dL, p = 0.002).Discussion
Disease control and organ function preservation repre-
sent important goals of treatment in advanced oropha-
ryngeal carcinomas. The increased use of combined
treatment approach by addition of chemotherapy to
radiotherapy either as induction chemotherapy [44,45]
or concurrent chemotherapy [23,24] has been shown to
result in improvement in LRC and OS in patients with
stage III-IV oropharyngeal cancer. Radiotherapy given
concurrently with chemotherapy is considered best
established definitive treatment approach for anatomic
and functional organ preservation in locally-regionally
advanced lesions arising from oropharynx and other



















Figure 4 Regional relapse-free survival according to N stage
(Kaplan-Meier estimates). Log-rank test; Chi square = 29.04;
p< 0.0001.Apart from the GORTEC 94-01 study [23,24] that docu-
mented the statistically significant survival benefit for
CRCT and strongly supported its employment in the man-
agement of carcinoma of the oropharynx, few other rando-
mized studies were conducted to evaluate the role of
CRCT in the treatment of advanced oropharyngeal carcin-
oma [25,47,48]. In the randomized phase III trial (ORO
93-01) comparing conventionally fractionated radiotherapy
vs. accelerated hyperfractionated radiotherapy vs. radio-
therapy with conventional fractionation plus concomitant
chemotherapy using carboplatin and 5-fluorouracil in
patients with advanced oropharyngeal cancer, significantly
superior 2-year DFS was found in the group treated with
CRCT [47]. Although the long-term results of ORO 93-01
trial did not reveal any statistical significance in terms of
LRC, relapse-free survival, and OS among groups treated
with conventional fractionation, altered fractionation and
CRCT, the authors concluded that considering the almost
double increase in the 5-year LRC, relapse-free survival,
and OS rates achieved with the use of CRCT, this com-
bined treatment approach should be recommended for
patients with advanced squamous cell carcinomas of the
oropharynx [48]. The results of prospective phase II rando-
mized single-centre study conducted by Sharma et al. [25]
comparing radical radiotherapy with CRCT with seven
doses of weekly cisplatin in patients with advanced carcin-
oma of the oropharynx and nasopharynx confirmed the su-
periority of CRCT over radiotherapy alone resulting in
higher OS rates.
In the present study of CRCT using 3DCRT and con-
current weekly cisplatin the observed 2-year rates of
LRFS, RRFS, LRRFS, DFS, and OS were 48.8%, 57.8%,
41.7%, 33.2% and 49.7%, respectively.
Calais et al. [23] reporting the results of GORTEC 94-01
trial in which conventionally fractionated radiotherapy was
given with concurrent chemotherapy consisting of three
cycles of carboplatin and 5-fluorouracil in patients with
Table 4 Univariate analysis correlating prognostic factors
with disease-free and overall survival
Factor DFS OS
n 2 years% p-value 2 years% p-value
Gender
Male 59 25.9 0,0711 45.4 0,1789
Female 6 83.4 83.3
Age (years)
≤ 50 20 27.8 0,8528 52.5 0,9873
> 50 45 34.7 49.8
Performance status (ECOG)
0 44 46.5 <0.0001 65.9 <0.0001
1 21 0 11.6
Cigarette smoking
Non-smokers 11 72.2 0,0323 72.8 0,1421
Current smokers 54 23.8 43.4
Alcohol consumption
Non-drinkers 25 56.5 0,0080 65.9 0,0333
Current drinkers 40 19.1 39.7
Subsite
Tonsil 36 29.3 0,4396 53.4 0,3679
Base of tongue 21 41.8 47.2
Soft palate 6 0 50.3
Posterior pharyngeal wall 2 0 0
T stage
T2-3 47 43.4 0,0033 57.2 0,0455
T4 18 0 39.7
N stage
N0-1 34 50.9 0.0004 73.4 0.0004
N2-3 31 14.1 26.6
Overall stage
III 23 70.3 <0.0001 80.3 0.0006
IVA-B 42 12.2 30.8
Histological differentiation
Well 22 40.9 0,1056 51.6 0,1287
Moderate 25 41.6 63.4
Poor 18 10.3 32.2
Haemoglobin level
≤ 12.5 g/dL 20 14.7 <0.0001 19.7 <0.0001
> 12.5 g/dL 45 41.6 63.8
n, number of patients; DFS, disease-free survival; OS, overall survival; ECOG,
Eastern Cooperative Oncology Group.
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http://www.ro-journal.com/content/7/1/78advanced-stage oropharynx carcinoma, revealed that 3-year
DFS rate was 42%, and a rate of 3-year OS was 50%, while
the observed rate of LRC was 66%. These figures are super-
ior to those obtained at 2 years in our study. The 5-year
analysis of the data of GORTEC 94-01 study reported byDenis et al. [24] confirming the significant improvement in
LRC and survival among patients with stage III and IV
squamous cell oropharyngeal carcinoma treated with
CRCT compared with those treated with radiotherapy
alone, showed 5-year LCR rate of 47.6%, specific disease-
free survival rate of 26.6%, and OS rate of 22.4% in the
combined therapy group.
In the prospective randomized trial conducted by Gupta
et al. [30] comparing induction chemotherapy followed by
CRCT with CRCT, 57 patients with locally advanced oro-
pharyngeal carcinoma were treated with a total dose of ir-
radiation between 65 and 70 Gy and concurrent low dose
cisplatin (35 mg/m2 weekly). Despite the fact that this regi-
men of CRCT is comparable with that used in the present
study, differences exist in the rates of LRC and survival in
favour of the study of Gupta with reported 2-year rates of
LRC, DFS, and OS of 83%, 59.5%, and 70%, respectively.
In the retrospective study of Kokubo et al. [49], the
achieved 3-year cause specific survival rate was 83% for
14 patients treated with CRCT using weekly cisplatin at
least 3 times. CRCT utilizing 3DCRT and concomitant
S-1 as an oral fluoropyrimidine in 38 patients with oro-
pharyngeal carcinoma resulted in 3-year LRC, distant
metastases-free survival, DFS, and OS rates of 75%, 80%,
65%, and 80%, respectively [50]. These reported higher
rates of disease control in comparison with the results of
our study could be partially attributable to the inclusion
of patients with stage I and II oropharyngeal cancer.
In the retrospective study of Lee et al. [51] comparing
efficacy of IMRT with conventional radiotherapy using
delayed accelerated concomitant boost radiotherapy in
the setting of concurrent platinum-based chemotherapy
for locally advanced oropharyngeal carcinoma, the im-
plementation of IMRT given with concurrent adminis-
tration of cisplatin every 3 to 4 weeks in 41 patients with
stage III/IV disease led to 3-year local-progression-free,
regional-progression-free, locoregional progression-free,
distant-metastases-free, disease-free, and OS rates of
95%, 94%, 92%, 86%, 82%, and 91%, respectively. These
results regarding both LRC and survival are remarkably
superior to the results obtained in our study.
Reviewing treatment outcomes for stage III and IV
oropharyngeal carcinoma treated with IMRT and con-
current platinum-based chemotherapy, de Arruda et al.
[36] and Huang et al. [37] also reported much better
results compared with the results of our study with re-
spect to local, regional, LRC and survival. High rates of
3-year disease-free and locoregional recurrence-free sur-
vivals (88% and 96%, respectively) have been also
achieved in the prospective study of Feng et al. [38]
assessing results of radiochemotherapy utilizing IMRT
and weekly chemotherapy with carboplatin and pacli-
taxel in 73 patients with stages III to IV oropharyngeal
carcinoma.



















Figure 6 Disease-free survival according to T stage (Kaplan-
Meier estimates) Log-rank test; Chi square = 8.610; p = 0.0033.
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http://www.ro-journal.com/content/7/1/78In the present study we found dose delivery of both
radiotherapy and chemotherapy quite satisfactory with
full planned dose of 70 Gy administered in all treated
patients and seven cycles of concurrent chemotherapy
completed in 60% of patients. However, the use of sin-
gle agent taxane-based CRCT for patients with
advanced head and neck cancer resulting in good re-
sponse rates and survival [52,53] has been shown as
well tolerated regimen [54]. Implemented in the treat-
ment of stage III-IV oropharyngeal carcinoma, concur-
rent taxane-based chemotherapy has provided superior
compliance as compared with that observed in the
present study. Thus, in the retrospective, single institu-
tion study of Fukada et al. [55] exploring taxane based
CRCT for the treatment of locally advanced oropharyngeal
or hypopharyngeal carcinoma, the 6-cycle program of
weekly low-dose docetaxel-based concurrent chemother-
apy was realized in 80% of patients while in the phase II
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Figure 7 Overall survival according to pre-treatment
haemoglobin concentration (Kaplan-Meier estimates) Log-rank
test; Chi square = 19.66; p< 0.0001.least five cycles of weekly paclitaxel even though the drug
was administered in a concurrent setting following induc-
tion chemotherapy [45]. Nevertheless, in a recently pub-
lished nonrandomized small sample size study comparing
low dose weekly paclitaxel versus low dose weekly cisplatin
given concurrently with conventionally fractionated radio-
therapy in locally advanced head and neck, both regimens
were found equally well tolerated [56].
Despite the noted changes in patterns of failure in
patients with head and cancer by some authors [57,58],
the results of our study with the observed local and/or
regional recurrence in 19 of 25 patients who manifested
treatment failure (76%) correspond with historical data
showing locoregional failure as the major problem in
disease control [23,24,29,58]. The reported data on dis-
tant failure in studies on CRCT for advanced oropharyn-
geal cancer range between 32% to 53% [23,24,29,58]. In
our study, distant metastases were recognized in 8 out
of 25 patients (32%) who manifested treatment failure at
some period after the achieved complete remission.
Considering the impact of clinical factors on treatment
outcomes, the prognostic analysis in our study revealed
overall stage as an independent factor strongly corre-
lated with LRC and survival. Stage IVA-B was found to
negatively influence LRFS, LRRFS, and DFS. Multivariate
analysis in the study of Denis et al. [24] also showed
stage IV disease as an important factor for short sur-
vival. The results of multivariate analysis in the study of
Ho et al. [59] have also presented overall clinical stage as
one of the strongest factors for survival.
In the multivariate analysis of our study, higher nodal
stage (N2-N3 vs. N0-N1) was shown as independent
prognostic factor only for poorer RRFS. In the study of
Fukada et al. [55], stage N2c-N3 disease was recognized
as influencing only OS. Agarwal et al. [60] found
advanced nodal disease independently prognostic for in-
ferior LRC and DFS. N stage was found to be an inde-
pendent significant factor for local, regional, LRC, DFS
and OS in the study of Johansen et al. [61]. Similarly,
Perez et al. [62] also showed that N stage was one of the
most significant independent factors affecting local and/
or regional tumour control and DFS.
The results of multivariate analysis in our study showed
that low pre-treatment haemoglobin concentration (≤ 12.5
g/dL) was independent prognostic factor negatively influ-
encing LRFS, RRFS, LRRFS, DFS, and OS. In the study of
Johansen et al. [61], haemoglobin level was found to be sig-
nificant only for local tumour control. Multivariate analysis
in the study of Denis et al. [24] revealed low haemoglobin
level as the most negative factor for LRC, DFS, and OS.
These results correspond with the results of multivariate
analysis in the study of Fukada et al. [55] identifying an-
aemia as a significant negative independent factor for LRC
and survival. The review of Kumar [63] has also revealed a
Table 5 Multivariate analysis for local relapse-free survival, regional relapse-free survival and locoregional relapse-free
survival
Factors Hazard ratio (95% CI)
LRFS RRFS LRRFS
Performance status (ECOG)(1 vs. 0) 1.11 (0.48-2.55) p = 0.806 0.67 (0.25-1.82) p = 0.431 1.12 (0.50-2.54) p = 0.779
Cigarette smoking(current smokers vs. non-smokers) / 3.98 (0.42-37.89) p = 0.229 0.61 (0.15-2.45) p = 0.485
Alcohol consumption(current drinkers vs. non-drinkers) 1.35 (0.57-3.20) p = 0.503 0.81 (0.25-2.63) p = 0.723 1.71 (0.61-4.84) p = 0.308
T stage(T4 vs. T2-3) / / 0.58 (0.22-1.52) p = 0.265
N stage(N2-3 vs. N0-1) 1.13 (0.44-2.89) p = 0.803 7.68 (1.02-58.05) p=0.048 0.73 (0.23-2.25) p = 0.577
Overall stage(IVA-B vs. III) 4.49 (1.24-16.27) p=0.022 3.57 (0.21-60.76) p = 0.379 9.91 (2.16-45.42) p=0.003
Haemoglobin level≤ 12.5 g/dL vs. > 12.5 g/dL 0.26 (0.11-0.62) p=0.002 0.27 (0.09-0.82) p=0.021 0.24 (0.10-0.57) p=0.001
95% CI, 95% confidence interval; LRFS, local relapse-free survival; RRFS, regional relapse-free survival; LRRFS, locoregional relapse-free survival; ECOG, Eastern
Cooperative Oncology Group.
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http://www.ro-journal.com/content/7/1/78strong evidence that low pre-treatment haemoglobin con-
centration as powerful, statistically significant prognostic
factor had negative impact on local control and survival in
head and neck cancer patients treated with definitive radio-
therapy. The impact of anaemia on locoregional tumour
control and survival in patients with squamous cell carcin-
oma of the larynx and pharynx was confirmed in the large
DAHANCA study in which the use of the radiosensitizer
nimorazole in association with radiotherapy was shown to
significantly improve LRC and disease-specific survival
[64]. According to Becker et al. [65], low haemoglobin con-
centration as a factor with a negative impact on treatment
outcomes was associated with reduced tumour oxygen-
ation resulting in radioresistance in head and neck cancer.
The analysis of the relationship between pre-treatment
measurements of tumour oxygen tension (pO2) and LRC
and survival provided evidence that tumour hypoxia was
associated with a poor prognosis in patients with advanced
head and neck squamous cell carcinoma treated with
radiotherapy [66,67]. The investigation of Nordsmark and
Overgaard [68] confirmed pre-treatment haemoglobin
level and tumour hypoxia prognostic for locoregional
tumour control emphasizing that low level of tumour oxy-
genation was shown the strongest independent prognosticTable 6 Multivariate analysis for disease-free survival and ove
Factors
Performance status (ECOG)(1 vs. 0)
Cigarette smoking(current smokers vs. non-smokers)
Alcohol consumption(current drinkers vs. non-drinkers)
T stage(T4 vs. T2-3)
N stage(N2-3 vs. N0-1)
Overall stage(IVA-B vs. III)
Haemoglobin level≤ 12.5 g/dL vs. > 12.5 g/dL
95% CI, 95% confidence interval; DFS, disease-free survival; OS, overall survival; ECOindicator for locoregional tumour control after definitive
radiotherapy in advanced head and neck cancers.
Although the recent re-analysis of a large randomized
trial conducted by DAHANCA [69] suggested that HPV
positive oropharyngeal cancers most probably would not
benefit from any modification of tumour oxygenation, it
should be pointed out that in conditions without available
data regarding HPV status, the reversal of anaemia should
be strongly considered in all patients with advanced oro-
pharyngeal carcinoma in order to eliminate the negative re-
flection of low pre-treatment haemoglobin level on the
patient’s general condition and tumour progression [63,70].
Considering the established importance of HPV,
expressed by p16, as a strong independent prognostic
factor for survival among patients with oropharyngeal
cancer [71], and taking into account published data indi-
cating HPV-positivity as consistent determinant of su-
perior survival irrespectively of the treatment approach
used [69,70,72,73] it could be admitted that specific test-
ing for HPV in oropharyngeal cancers is highly recom-
mendable since the combination of HPV status and
overall disease stage could be useful in further classifica-
tion of patients providing in that way treatment deci-
sions for individual patient moreover that the optimalrall survival
Hazard ratio (95% CI)
DFS OS
1.20 (0.56-2.60) p = 0.634 1.51 (0.59-3.86) p = 0.395
0.93 (0.25-3.41) p = 0.909 /
1.47 (0.59-3.63) p = 0.399 1.17 (0.49-2.77) p = 0.722
0.70 (0.28-1.72) p = 0.431 0.76 (0.29-2.02) p = 0.582
0.62 (0.22-1.74) p = 0.362 1.10 (0.30-4.11) p = 0.887
8.40 (2.11-33.47) p=0.003 3.82 (0.73-19.97)p = 0.112
0.28 (0.13-0.61) p=0.002 0.24 (0.10-0.60) p=0.002
G, Eastern Cooperative Oncology Group.
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http://www.ro-journal.com/content/7/1/78treatment regimen for HPV/p16 positive oropharyngeal
cancer has not been yet clarified.Conclusions
Our study, presenting single centre treatment experience,
demonstrated inferior results in patient outcomes following
single-agent weekly cisplatin radiochemotherapy regimen
compared with the results of studies evaluating CRCT
using the same or different scheduling of concomitant cis-
platin regardless of the radiation technique used. Results of
our study, especially when taking into consideration the
highest proportion of local/regional relapse in the whole
number of recurrences, do suggest that further progress in
the management of this disease in our institution could be
achieved by introduction of advanced radiotherapy techni-
ques (IMRT) as an attempt to reduce incidence of locore-
gional failures and to influence improvement of DFS and
OS rates. However, the high percentage of patients with
distant metastatic development with or without synchron-
ous manifestation of locoregional recurrence recognized in
studies of CRCT should not be neglected and should point
out the importance of further investigation of combined
treatment approach represented with induction chemo-
therapy followed by CRCT. Despite all uncertainties of
radiotherapy, the use of accelerated radiotherapy regimens
which can lead to redefinition of treatment protocols and
reorganization of patient and staff flow in the department,
can lead to improvement of treatment outcome. Also,
introduction of other cytotoxic agents (taxanes) in concur-
rent setting with conventional fractionated radiotherapy
and the inclusion of molecular targeted therapies are
expected to provide further improvement in treatment out-
comes in patients with advanced squamous cell carcinoma
of the oropharynx.Abbreviations
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